{
  "docId": "019de073-8606-762c-9e2e-06d280bc8199",
  "docSlug": "fe3546a131d6b03dbc05b580d2cda1c4",
  "documentTitle": "CTI BioPharma | Investor Presentation Deck | 24 slides",
  "authorId": "cti-biopharma",
  "authorName": "CTI BioPharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 3,
  "pageCount": 24,
  "prevPage": 2,
  "nextPage": 4,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 3,
  "notes": "Slide provides a snapshot of product approval, financial performance, and market opportunity.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-8606-762c-9e2e-06d280bc8199/3",
  "deckHref": "/decks/019de073-8606-762c-9e2e-06d280bc8199",
  "deckJsonHref": "/decks/019de073-8606-762c-9e2e-06d280bc8199.json",
  "deckAnchorHref": "/decks/019de073-8606-762c-9e2e-06d280bc8199#slide-3",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.7,
        "x": 0.23,
        "y": 0.89
      },
      "kind": "disclaimer",
      "text": "Continued approval may depend on demonstrating a clinical benefit in the PACIFICA trial. 1. NCCN Clinical Practice Guidelines for Myeloproliferative Neoplasms V2 2022. 2. Evaluate Pharma, 2019 US Sales by Indication.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "362cd8fd-4d64-43fd-b62a-e923cc77dbff",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.35,
        "x": 0.06,
        "y": 0.45
      },
      "kind": "list",
      "text": "Commercial launch underway",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1b6aea38-0838-491c-bd51-be0909b6f6f4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.06,
        "y": 0.79
      },
      "kind": "list",
      "text": "CTI continues to explore new indications and development opportunities",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "53c90dd5-ac74-404c-88df-ee17b8645460",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.6,
        "x": 0.06,
        "y": 0.65
      },
      "kind": "list",
      "text": "$3B potential total addressable market in myelofibrosis by 2026",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ebc3bdb4-a0b0-4f50-b721-413c57c1c70c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.9,
        "x": 0.06,
        "y": 0.18
      },
      "kind": "list",
      "text": "VONJO (pacritinib) first FDA-approved treatment for cytopenic myelofibrosis",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f15ab339-56a2-43bf-9ef9-ee1049515d71",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.25,
        "x": 0.06,
        "y": 0.04
      },
      "kind": "title",
      "text": "CTI Overview",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "02be954e-6f56-4cf1-aa44-8a0d900c8a36",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "d8db9825-d40a-4d25-9d86-580c681a239f",
      "evidence": "title/headline: CTI Overview",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 3,
      "from": 1,
      "beatId": "84a70645-cc8e-415e-8baa-8027629c727e",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Setup",
      "beatSlug": "setup",
      "evidence": "Introduction to CTI BioPharma and VONJO",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 3,
      "from": 3,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "46057859-a3da-4c0b-949e-9d9e1b99808c",
      "evidence": "CTI Overview",
      "position": 1,
      "objective": "Explain why VONJO is a solution",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.5,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}